-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MJovqA91jr6AcVVyehbzmB+pW0Gp0hfsaqy8E0u//PIFgyDvugVOUG2kEeoTarvb
 IbDwNzBF4nHdj1T70dkiPw==

<SEC-DOCUMENT>0001279569-09-000041.txt : 20090113
<SEC-HEADER>0001279569-09-000041.hdr.sgml : 20090113
<ACCEPTANCE-DATETIME>20090113161206
ACCESSION NUMBER:		0001279569-09-000041
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090113
FILED AS OF DATE:		20090113
DATE AS OF CHANGE:		20090113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		09524082

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>oncolytics6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>
  <head>
    <title>oncolytics6k.htm</title>
<!-- Licensed to: CNW Group-->
<!-- Document Created using EDGARizer 4.0.6.4 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--
    PAGEBREAK -->

    <div style="FONT-FAMILY: 'Times New Roman',Times,serif">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
      <div style="FONT-SIZE: 14pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">SECURITIES AND<font size="+0" style="FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"> EXCHANGE</font>
COMMISSION</font><br></font></font></font></font><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Washington, D.C.
20549</font></div>
      <div style="FONT-SIZE: 12pt" align="center">&#160;</div>
      <div style="FONT-SIZE: 18pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">F<font size="+0" style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">orm</font>
6-K</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font size="+0">Pursuant to Rule</font>&#160;13a-16 or 15d-16<br>of the Securities
Exchange Act of 1934</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center">For the month of&#160;January 2009
</div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center">Commission File Number 000-31062
</div>
      <div>&#160;</div>
      <center>
        <div style="FONT-SIZE: 24pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">Onc<font size="+0" style="FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">oly</font>tics
Biotech Inc.</font></div>
        <hr style="COLOR: black" align="center" noshade size="1" width="45%">
        <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-STYLE: italic">(Translation of registrant&#8217;s name
into English)</font></div>
        <div style="FONT-SIZE: 10pt" align="center">&#160;</div>
      </center>
      <center>
        <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington
Crescent NW<br>Calgary, Alberta, Canada T2N 1X7</font></div>
        <hr style="COLOR: black" align="center" noshade size="1" width="45%">
        <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-STYLE: italic">(Address of principal executive
offices)</font></div>
        <div style="FONT-SIZE: 10pt" align="center">&#160;</div>
      </center>
      <div style="FONT-SIZE: 10pt">Indicate by check mark whether the registrant files
or will file annual reports under cover Form&#160;20-F or Form&#160;40-F. </div>
      <center>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" width="70%" style="FONT-SIZE: 10pt">
              <tr valign="bottom">
                <td width="49%">&#160;</td>
                <td width="2%">&#160;</td>
                <td width="49%">&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">
                  <div style="TEXT-ALIGN: center">Form&#160;20-F&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">&#254;</font></div>
                </td>
                <td>&#160;</td>
                <td valign="top">
                  <div style="TEXT-ALIGN: center">Form&#160;40-F&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
                </td>
              </tr>
          </table>
        </div>
      </center>
      <div style="FONT-SIZE: 10pt">&#160;</div>
      <div style="FONT-SIZE: 10pt">Indicate by check mark if the registrant is
submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T
Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if
submitted solely to provide an attached annual report to security holders.
</div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt">Indicate by check mark if the registrant is
submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T
Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if
submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form&#160;6-K submission or other
Commission filing on EDGAR. </div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&#160;12g3-2(b) under the
Securities Exchange Act of 1934. </div>
      <center>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" width="70%" style="FONT-SIZE: 10pt">
              <tr valign="bottom">
                <td width="49%">&#160;</td>
                <td width="2%">&#160;</td>
                <td width="49%">&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">
                  <div style="TEXT-ALIGN: center">Yes&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
                </td>
                <td>&#160;</td>
                <td valign="top">
                  <div style="TEXT-ALIGN: center">No&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">&#254;</font></div>
                </td>
              </tr>
          </table>
        </div>
      </center>
      <div style="FONT-SIZE: 10pt">&#160;</div>
      <div style="FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number
assigned to the registrant in connection with
Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
      <div>&#160;</div>
      <div>
      </div>
      <div>&#160;</div>
      <hr style="MARGIN-TOP: -2px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="4">
      <div style="FONT-SIZE: 10pt">
      </div>
      <div>&#160;</div>
    </div><!-- PAGEBREAK -->

    <div>
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div align="left">&#160;</div>
    <div>
    </div>
    <div>
    </div>
    <div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <table cellpadding="0" cellspacing="0" width="100%">
                    <tr>
                      <td align="left" valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">EXHIBIT</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">NUMBER</font></div>
                      </td>
                      <td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="bottom" width="68%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="top" width="68%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="6%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
                      </td>
                      <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="68%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">News Release Dated
      January 13, 2009 -</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics
      Biotech Inc. Announces Issuance of 31st U.S.
  Patent</font></font></div>
                      </td>
                    </tr>
                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div style="FONT-FAMILY: 'Times New Roman',Times,serif">
      <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SIGNATURES</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized. </div>
      <div>&#160;</div>
      <center>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt">
              <tr valign="bottom">
                <td width="50%">&#160;</td>
                <td width="1%">&#160;</td>
                <td width="1%">&#160;</td>
                <td width="1%">&#160;</td>
                <td width="47%">&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">&#160;</td>
                <td>&#160;</td>
                <td align="left" colspan="3" valign="top"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Oncolytics Biotech
      Inc.</font><br>(Registrant)</td>
              </tr>
              <tr>
                <td>&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">&#160;</td>
                <td>&#160;</td>
                <td align="left" valign="top">&#160;</td>
                <td>&#160;</td>
                <td align="left" valign="top">&#160;</td>
              </tr>
              <tr>
                <td>&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">Date:&#160;&#160;January 13, 2009 </td>
                <td>&#160;</td>
                <td align="left" valign="top">By:</td>
                <td>&#160;</td>
                <td align="left" valign="top">/s/&#160;&#160;Doug Ball

                  <hr style="COLOR: black" align="left" noshade size="1" width="60%">      Doug Ball<br>Chief Financial Officer</td>
              </tr>
          </table>
        </div>
      </center>
      <div style="FONT-SIZE: 10pt" align="center">
      </div>
      <div>&#160;</div>
    </div><!-- PAGEBREAK -->

    <div>
    </div>
    <div>&#160;</div>
  </body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JANUARY 13, 2009
<TEXT>
<html>
  <head>
    <title>ex991.htm</title>
<!-- Licensed to: CNW Group-->
<!-- Document Created using EDGARizer 4.0.6.4 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div>
      <pre>Exhibit 99.1</pre>
      <pre>News release via Canada NewsWire, Toronto 416-863-9350

	    Attention Business Editors:
	    Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent

	    CALGARY, Jan. 13 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)
("Oncolytics") today announced that it has been granted its 31st U.S. Patent,
No. 7,476,382, entitled "Reovirus for the Treatment of Neoplasia." The patent
includes claims to pharmaceutical compositions containing reovirus.
	    "This U.S. patent expands and strengthens our proprietary position for
REOLYSIN(R)," said Mary Ann Dillahunty, Vice President of Intellectual
Property for Oncolytics. "The pharmaceutical composition claims cover the
formulation being used in our ongoing clinical trials."

	    About Oncolytics Biotech Inc.

	    Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. Oncolytics'
clinical program includes a variety of Phase I/II and Phase II human trials
using REOLYSIN(R), its proprietary formulation of the human reovirus, alone
and in combination with radiation or chemotherapy. For further information
about Oncolytics, please visit www.oncolyticsbiotech.com

	    This news release contains forward-looking statements, within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including among others, the Company's belief as to
the importance of the issuance of this patent, the safety and efficacy of the
reovirus, the Company's expectations as to the potential applications of the
patented technology and other statements relating to anticipated developments
in the Company's business and technologies, involve known and unknown risks
and uncertainties that could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer
treatment, the success and timely completion of clinical studies and trials,
uncertainties related to the research and development of pharmaceuticals and
uncertainties related to the regulatory process. Investors should consult the
Company's quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements. The Company does not undertake to
update these forward-looking statements, except as required by applicable
laws.

	    %SEDAR: 00013081E          %CIK: 0001130319

	    /For further information: Oncolytics Biotech Inc.: Cathy Ward, 210, 1167
Kensington Cr NW, Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403)
283-0858, cathy.ward(at)oncolytics.ca; The Equicom Group: Nick Hurst, 325, 300
5th Ave SW, Calgary, Alberta, T2P 3C4, Tel: (403) 538-4845, Fax: (403)
237-6916, nhurst(at)equicomgroup.com; The Investor Relations Group: Erika Moran,
11 Stone St, 3rd Floor, New York, NY, 10004, Tel: (212) 825-3210, Fax: (212)
825-3229, emoran(at)investorrelationsgroup.com/
	    (ONC. ONCY)

CO:  Oncolytics Biotech Inc.

CNW 07:30e 13-JAN-09

</pre>
    </div>
  </body>
</html>


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
